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SupplementationAbstract Multi-drug-resistant tuberculosis (MDR-TB) is caused by Mycobacterium tuberculosis
(Mtb) strain resistant to both rifampicin and isoniazid. Nigeria has an estimated MDR-TB rate
of 2.9% and 14.3% among new and relapse cases respectively and is ranked among 4 high burden
African countries for MDR-TB. Malnutrition has been implicated in the progression from dormant
to active disease.
This study determined the plasma level of micronutrients (Fe, Zn, Cu, vitamins A, C, D and E) in
MDR-TB patients before and throughout anti-TB chemotherapy. Plasma iron, zinc, copper, vita-
mins A, C, D and E were determined in twenty-four (24) MDR-TB patients before the commence-
ment of anti-TB chemotherapy, 2 months, 4 months and 6 months post-commencement of anti-TB
chemotherapy, as well as in twenty (20) healthy controls. Plasma vitamin A level was significantly
decreased before chemotherapy compared with controls. At 2 months of anti-TB treatment there
were significant decreases in plasma levels of iron, vitamins A, C and E compared to controls
whereas plasma zinc level was significantly increased compared with levels before treatment. At
4 months of treatment, plasma levels of copper and vitamin D were significantly increased while
plasma vitamin E level was reduced significantly compared with controls. There were significant
increases in iron, zinc, copper, vitamin A and vitamin D levels with decreased plasma levels of vita-
mins C and E at 4 months of treatment compared with their levels before chemotherapy. At
6 months of treatment, plasma levels of iron, zinc, copper and vitamin D were significantly
increased while vitamin E was significantly decreased compared with controls. Plasma levels of iron,
zinc, copper, vitamins A and D were significantly increased whereas the levels of vitamins C and E
were significantly reduced at 6 months of treatment compared with levels before chemotherapy.
442 V.F. Edem et al.Plasma levels of iron, zinc, copper, vitamins A and D were raised while plasma levels of vitamins
E and C were reduced in MDR-TB patients from 4 months post commencement of anti-TB
chemotherapy. Thus, there is need to monitor micronutrient supplementation and plasma levels
of these micronutrients to avoid complications associated with overload or deficiency.
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Tuberculosis (TB) continues to be a major public health chal-
lenge globally and now ranks alongside HIV as a leading cause
of death worldwide [1]. Recent statistics show a rise in the
number of new TB cases from 9 million in 2013 to 9.6 million
in 2014 with the number of TB associated deaths in 2013 and
2014 remaining constant at 1.5 million [1,2]. In recent years,
progress in TB control and eradication has been threatened
by the emergence of drug resistant strains of Mycobacterium
tuberculosis (Mtb). Multi-drug-resistant tuberculosis (MDR-
TB) is defined as a disease caused by Mtb strain resistant to
both rifampicin and isoniazid, which are frontline anti-
tuberculosis drugs presently used in chemotherapy. Nigeria is
reported to have an estimated MDR-TB rate of 2.9% and
14.3% among new and relapse cases respectively and is ranked
among 4 high burden African countries for MDR-TB [3].
Among other factors, malnutrition has been implicated in
the progression from dormant to active disease [4].
The innate immune cells; macrophages, neutrophils and
dendritic cells, play an important role in immunological
response, as first responder, activator of adaptive immunity
and effector cell in Mtb infection [5]. Mtb bacilli upon entry
into the lungs are engulfed by resident innate immune cells
(macrophages and dendritic cells). This leads to transforma-
tion of macrophages from a resting state to an activated state
with characteristic feature of increased oxygen uptake, enlarge-
ment and increased protein synthesis [6]. Also there is
increased influx of neutrophils to the lungs, and a report
demonstrated that neutrophils are the most commonly infected
phagocytes in human TB [7]. Macrophage and neutrophil
apoptosis have also been reported to be a potent mechanism
for control of inflammation and removal of infected cells in
Mtb infection [8]. These lead to a high rate of cellular turnover
during infection and increased demand for essential nutrients
by the immune cells [9].
A close relationship was suggested between micronutrients
and modulation of neutrophil and macrophage functions
[10]. Micronutrient malnutrition has been described in pul-
monary TB patients [11–14] and several studies have sug-
gested that patients with TB are at high risk of deficiency
of vitamins A, C, D and E as well as zinc [13,14]. Our pre-
vious study [15] reported micronutrient malnutrition in
patients with drug-sensitive TB at diagnosis and throughout
the period of anti-TB chemotherapy. Because micronutrient
deficiency has been reported to impair resistance to infection,
lead to active TB disease and poor outcome of anti-TB
chemotherapy, this present study therefore determined the
plasma level of micronutrients (Fe, Zn, Cu, vitamins A, C,
D and E) in MDR-TB patients before and throughout
anti-TB chemotherapy.Materials and method
Study participants
Twenty-four (24) patients admitted into the MDR TB center,
University College Hospital (UCH) Ibadan, Nigeria for
anti-TB treatment were recruited for the study after obtaining
written informed consent. Patients had been previously diag-
nosed as being infected with isoniazid and rifampicin resistant
strains of Mtb using clinical history, chest X-ray and GENE
Xpert test. Twenty (20) apparently healthy participants were
recruited as controls. Five (5) milliliters of blood was drawn
from the anti cubital fossa vien into lithium heparin tubes
before the commencement of chemotherapy, and 2 months,
4 months and 6 months of anti-TB therapy. Blood samples
were centrifuged and plasma obtained was analyzed.
MDR-TB treatment protocol
All bacteriologically confirmed MDR-TB patients received
intensive phase for 6–8 months in the hospital followed by
12 months of continuation phase in the community based on
WHO updated guidelines in 2011 [16]. Standardized treatment
regimen was used including five drugs: kanamycin/Amikacin,
Levofloxacin, Prothionamide, Cycloserine, Pyrazinamide (with
Pyridoxine). This present study was conducted during the
intensive phase of treatment.
While patients were admitted for MDR-TB treatment, they
were supported by non-governmental organizations which
provided nutritional support in the form of meals and
micronutrient supplements. Vitamin C (Spartan C), folic acid
(Vitabiotics), vitamin B complex (Vitabiotics), vitamin B6
(Pauco) and multivit (Pauco) supplements were administered
daily with anti-TB drugs as part of the treatment regimen at
the center where this study was conducted.
Micronutrient analysis
Plasma levels of micronutrient vitamins (A, C, D and E) were
determined by high performance liquid chromatography
method using WATERS 616/626 (USA) machine as previously
carried out [17].
Plasma concentrations of trace metals (Fe, Zn and Cu) were
determined using atomic absorption spectrophotometry (Buck
Scientific, 210, Atomic Absorption Spectrophotometer, Con-
necticut, USA) as previously described [15].
Statistical analysis
Data obtained were analyzed using statistical package for
social sciences (SPSS) version 17.0. Independent Student
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patients and controls while paired t-test was used to compare
the mean values of MDR TB patients before the commence-
ment of chemotherapy, and 2 months, 4 months and 6 months
of anti-TB chemotherapy. Values were considered significant
at p< 0.05.
Results
Plasma vitamin A level was significantly decreased before the
commencement of chemotherapy compared with controls. At
2 months of anti-TB treatment regimen, there were significant
decreases in plasma levels of iron, and vitamins A, C and E
when compared to controls whereas plasma zinc level was
significantly increased when compared with levels before treat-
ment. At 4 months of treatment the plasma levels of copper
and vitamin D were significantly increased while plasma vita-
min E level was reduced significantly when compared with con-
trols. There were also significant increases in iron, zinc, copper,
vitamin A and vitamin D levels with decreased plasma levels of
vitamins C and E at 4 months of treatment when compared
with their levels before the commencement of chemotherapy.
At 6 months of treatment, the plasma levels of iron, zinc,
copper and vitamin D were significantly increased while
vitamin E was significantly decreased when compared with
controls. Plasma levels of iron, zinc, copper, and vitamins A
and D were significantly increased whereas the levels of
vitamins C and E were significantly reduced at 6 months
of treatment compared with levels before the commencement
of chemotherapy (see Table 1).
Discussion
Most previous micronutrient supplementation studies in TB
patients concentrated on drug sensitive TB patients and
assessed effects of micronutrient supplementation on mortal-
ity, sputum culture conversion, chest X-ray resolution, weight
gain and bacterial clearance [18]. These studies produced
inconsistent results. In this present study plasma vitamin A
concentration was significantly reduced in patients before the
commencement of chemotherapy compared with control. This
supports previous findings in drug-sensitive TB patients
[14,15]. However, significantly reduced levels of micronutrients
(Fe, Zn, Cu, vitamins C, D and E) observed in drug-sensitive
TB patients before chemotherapy compared with controls inTable 1 Plasma concentrations of micronutrients in MDR-TB patie
Parameters Control Before chemotherapy
Iron (lg/dl) 98.76 ± 3.64 92.17 ± 10.47
Zinc (lg/dl) 66.27 ± 9.85 62.57 ± 4.63
Copper(lg/dl) 97.18 ± 7.38 96.33 ± 9.59
Vitamin A (lg/dl) 71.78 ± 20.28 49.81 ± 11.43*
Vitamin C (mg/dl) 1.82 ± 1.07 2.40 ± 0.52
Vitamin D (pg/ml) 45.80 ± 13.30 44.08 ± 9.58
Vitamin E (mg/dl) 2.04 ± 0.52 2.16 ± 0.59
PC – post commencement of chemotherapy.
* Significantly different from control (p< 0.05).
o Significantly different from before commencement of chemotherapy (our previous study [15] was not observed in this present study.
This might be due to differing severity or class of TB. The pre-
sent patients were MDR-TB patients while the previous were
drug-sensitive TB patients. MDR-TB patients might have been
using conventional or herbal-traditional medicines which may
be rich in micronutrients [19–21] during the waiting period
before hospital admission in a bid to better their health and
resolve TB symptoms. Vitamin A has been shown to inhibit
multiplication of Mtb in macrophages in vitro [22,23] and plays
a vital role in lymphocyte proliferation and maintaining the
function of epithelial tissues [24]. However, vitamin A defi-
ciency is a common feature of pulmonary tuberculosis.
Reduced plasma vitamin A concentration observed before
chemotherapy in this present study might be due to reduced
intake, reduced absorption, increased utilization, increased uri-
nary excretion of vitamin A or a combination of these factors
as demonstrated in other infections.
Following the commencement of anti-TB treatment com-
bined with micronutrient supplementation, this present study
observed reduced plasma concentrations of iron and vitamins
A, C and E in MDR-TB patients at two months of chemother-
apy compared with controls. This finding is similar to our pre-
vious study [15] on drug-sensitive TB patients on standard
anti-TB treatment without micronutrient supplementation.
To explain this observation, we suggested possible drug–
micronutrient interaction or drug induced nutrient depletion
[15] within the first two months post commencement of anti-
TB chemotherapy. Though a study [25] reported a modulating
effect of rifampicin on nutritional supplements, the nature and
mechanism of interaction between the anti-TB drugs and
micronutrients are still largely unclear. Plasma levels of copper
and vitamin D increased at 4 months post commencement of
treatment with increased concentrations of iron, zinc, copper
and vitamin D at 6 months post commencement of treatment
when compared with controls. Also, from 4 months post com-
mencement of treatment the levels of iron, zinc, copper, and
vitamins A and D concentrations increased when compared
to controls or before chemotherapy. This observation is similar
to our previous report in drug-sensitive TB patients [15]. This
might be due to adaptation to continuous drug use. This pre-
sent study also supports the findings of Kassu et al. [26] that
serum levels of trace elements in TB patients increased after
the treatment when compared to their levels before treatment.
The pathogenesis of lung fibrosis and dysfunction in TB has
been associated with induced production of oxidative sub-
stances such as reactive oxygen species (ROS) derived fromnts before chemotherapy, during treatment, and healthy controls.
2 months PC 4 months PC 6 months PC
89.12 ± 8.02* 106.12 ± 11.70o 131.44 ± 11.68*,o
68.36 ± 4.49o 79.81 ± 25.59o 114.73 ± 17.72*,o
100.35 ± 4.87 110.09 ± 14.74*,o 132.33 ± 14.30*,o
54.79 ± 9.55* 73.67 ± 11.50o 80.91 ± 5.63o
1.04 ± 0.83*,o 1.62 ± 1.11o 2.03 ± 0.53o
45.02 ± 11.84 64.04 ± 13.85*,o 62.73 ± 9.24*,o
1.03 ± 0.53*,o 0.94 ± 0.48*,o 0.83 ± 0.18*,o
p< 0.05).
444 V.F. Edem et al.free radicals, which in turn can promote tissue injury and
inflammation. ROS are highly toxic to all types of cells, but
especially to lipids causing peroxidation which results in dam-
age to cell membranes [27,28]. Antioxidants in different forms
scavenge free radicals and suppress the actions of ROS, pro-
tecting the host from tissue inflammation. Vitamins C (ascor-
bic acid) and E (alpha tocopherol) act as potent and
probably the most important hydrophilic and lipophilic
antioxidants respectively. Vitamin C scavenges superoxide rad-
ical, hydrogen peroxide and thiol radicals and is a potent
quencher of singlet oxygen while vitamin E converts superox-
ide radical, hydroxyl and lipid peroxyl radicals to less reactive
forms [27]. It has been demonstrated that vitamin E acts as a
mobilizable antioxidant being released from tissue stores and
diverted to lungs of TB patients during oxidative stress and
radical mediated pulmonary fibrosis [29]. This leads to the for-
mation of tocopherol radical which is converted to tocopherol
by ascorbic acid (vitamin C), thereby conferring vitamin E
sparing ability on vitamin C [30]. In this present study, plasma
concentrations of vitamin E were reduced at 2 months,
4 months and 6 months of anti-TB treatment when compared
to controls or before the commencement of anti-TB
chemotherapy while plasma vitamin C concentrations were
reduced at 2 months when compared to controls or at
2 months, 4 months and 6 months when compared to before
the commencement of chemotherapy. Despite supplementa-
tion of TB chemotherapy with vitamins, the levels of vitamins
C and E were not raised as expected, therefore, there is need to
determine effective dosage of vitamins for supplementation in
MDR-TB patients.
Active TB disease has been associated with a low iron status
[14,15,26] which has been attributed to anemia resulting from
chronic inflammation or a shift of iron from transferrin-bound
available state to a ferritin-incorporated storage state [26]. This
shift may have evolved as a cytokine-mediated defense against
microbial pathogen to effectively withholding iron from
microbes [31]. In our previous study, we suggested that caution
be exercised in the supplementation of iron in TB patients [15].
Increased levels of iron and copper from 4 months after the
commencement of treatment observed in this present study
underscores a need for reduction in the dosage of iron and cop-
per supplements administered to MDR-TB patients. Iron and
copper are pro-oxidants which produce toxic and indiscrimi-
nately reactive hydroxyl radical from hydrogen peroxide by
Fenton chemistry [32]. This may also explain the low levels
of vitamins C and E observed in these patients due to increased
scavenging of resulting ROS. In a previous prospective study
of the relationship between TB and increased dietary iron,
increased dietary iron was associated with a 3.5-fold increase
in estimated odds of developing active TB and a trend toward
higher mortality among TB patients [33]. Also, free iron is used
by microbes to thrive [34], excessive iron in MDR-TB patients
might explain susceptibility to continuous TB and other infec-
tious agents. Moreover, Mtb uses iron as prosthetic group for
superoxide dismutase which transfers free electron from super-
oxide to form hydrogen peroxide [35]. Superoxide is a more
potent antibacterial agent than hydrogen peroxide. Moreover,
hydrogen peroxide is easily converted to water by catalase in
Mtb [35]. Based on this, excess iron in MDR-TB patients
may be one of the factors used by resistant Mtb to evade res-
piratory burst mechanism employed by phagocytes to kill
ingested Mtb.In conclusion, multi-micronutrient supplementation of
MDR-TB patients on anti-TB chemotherapy raised plasma
levels of iron, zinc, copper, and vitamins A and D from
4 months post commencement of anti-TB chemotherapy.
Thus, there is need to monitor micronutrient supplementation
and plasma levels of these micronutrients to avoid complica-
tions associated with overload or deficiency.
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